Literature DB >> 5640675

Clinical pharmacologic observations on 6-mercaptopurine and 6-methylthiopurine ribonucleoside.

T L Loo, J K Luce, M P Sullivan, E Frei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5640675     DOI： 10.1002/cpt196892180

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  12 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

2.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

3.  Diminished antiviral effect of human interferon in the presence of therapeutic concentrations of antineoplastic agents.

Authors:  T C Cesario; L M Slater
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

Review 4.  Clinical pharmacokinetics of methotrexate in children.

Authors:  Y M Wang; T Fujimoto
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 5.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia.

Authors:  P Lafolie; O Björk; S Hayder; L Ahström; C Peterson
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 7.  The thiopurines: an update.

Authors:  Sally Coulthard; Linda Hogarth
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

8.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.

Authors:  A Hageboutros; G R Hudes; J Brennan; F Green; J Hoffman; F P LaCreta; J Colofiore; D S Martin; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

9.  The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog.

Authors:  K Lu; T L Loo
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

10.  Assay of azathioprine, 6-mercaptopurine and a novel thiopurine metabolite in human plasma.

Authors:  J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.